Patient-Driven Drug Development
Patient-driven drug development is an emerging approach to pharmaceutical research that is forged in rare-disease communities and patient advocacy networks. Patients and their advocates increasingly engage in drug discovery and influence early-stage drug research as clinical trial participants or through compassionate-use programs. Some advocacy groups and patients also influence which therapies are developed by financing promising treatments that otherwise would not secure funding. Though some critics of patient-driven drug development worry about the ethical and scientific implications of this new approach to research, it also has several advantages over the current system. In this essay I argue that patient-driven drug development is morally permissible.
KeywordsDrug Development Experimental Drug Clinical Trial Participant Venture Philanthropy Unapproved Drug
- “About | iCancer”. 2015. http://icancer.org.uk/about/. Accessed 27 Apr 2015.
- Carroll, J. 2015, January 20. CytRx Surges after FDA Lifts a Partial Hold on Late-Stage Cancer Drug. Fierce Biotech. http://www.fiercebiotech.com/story/cytrx-surges-after-fda-lifts-partial-hold-late-stage-cancer-drug/2015-01-20. Accessed 29 Apr 2015.
- Cha, A.E. 2014, March 23. Crowdsourcing Medical Decisions: Ethicists Worry Josh Hardy Case May Set Bad Precedent. The Washington Post.Google Scholar
- Committee on Bioethics. 1995. Informed Consent, Parental Permission, and Assent in Pediatric Practice. Pediatrics 95(2): 314–317.Google Scholar
- Dwamena, F., M. Holmes-Rovner, C.M. Gaulden, S. Jorgenson, G. Sadigh, A. Sikorskii, S. Lewin et al. 2012. Interventions for Providers to Promote a Patient-Centred Approach in Clinical Consultations. In Cochrane database of systematic reviews, ed. The Cochrane Collaboration. Chichester: Wiley. http://doi.wiley.com/10.1002/14651858.CD003267.pub2. Accessed 11 Aug 2016.
- Frydman, G.J. 2009. Patient-Driven Research: Rich Opportunities and Real Risks. Journal of Participatory Medicine 1(1): e12.Google Scholar
- Grabowski, H.G., and J.M. Vernon. 1983. The Regulation of Pharmaceuticals: Balancing the Benefits and Risks. Washington, DC: American Enterprise Institute for Public Policy Research.Google Scholar
- Greenhouse, L. 2008, January 15. Justices Won’t Hear Appeal on Drugs for Terminally Ill. The New York Times.Google Scholar
- Hinkes-Jones, L. 2015, January 5. Stop Subsidizing Big Pharma. The New York Times. Google Scholar
- Huebner, J.M. 2013. Moral Psychology and the Intuition That Pharmaceutical Companies Have a ‘Special’ Obligation to Society. Journal of Business Ethics 122(3): 501–510.Google Scholar
- Lichtenberg, F.R., and J. Waldfogel. 2008. Does Misery Love Company–Evidence from Pharmaceutical Markets before and after the Orphan Drug Act. Michigan Telecommunications and Technology Law Review 15: 335.Google Scholar
- ———. 2015a, March 2. Deaf or Death? In Drug Trial, Parents Weigh Life vs. Hearing Loss. Wall Street Journal.Google Scholar
- ———. 2015b. Niemann-Pick Type C: A Fight to Save Children with a Drug. The Wall Street Journal. http://on.wsj.com/1due624. Accessed 10 Mar 2015.
- Masters, A. 2015. A Plutocratic Proposal. Mosaic. http://mosaicscience.com/story/plutocratic-proposal. Accessed 7 Apr 2015.
- Morrow, K.J. 2015, April 25. Drug Development in the Age of Social Media. Life Science Leader.Google Scholar
- Pollack, A. 2007, August 8. Court Rejects the Right to Use Drugs Being Tested. The New York Times. Google Scholar
- Salmon, F. 2014, August 24. The Ice Bucket Challenge Isn’t Going Away: But Giving Money to Disease-Specific Charities Is Still a Bad Idea. Slate. http://www.slate.com/articles/business/moneybox/2014/08/als_ice_bucket_challenge_giving_money_to_disease_specific_charities_is_a.html. Accessed 29 Apr 2015.
- Sanghavi, D.M. 2013, October 31. How Dying Patients Get Access to Experimental Drugs. The New York Times. Google Scholar
- Scherer, F.M. 2000. The Pharmaceutical Industry. In Handbook of Health Economics, ed. A.J. Culyer and J.P. Newhouse, 1297–1336. 1st edition. Elsevier. http://www.sciencedirect.com/science/article/pii/S1574006400800384. Accessed 11 Aug 2016.
- Sofer, G.J. 2008, December 30. The FDA Is Killing Crohn’s Patients. Wall Street Journal. Google Scholar
- Thadhani, R. 2006. Formal Trials versus Observational Studies. In Fabry Disease: Perspectives from 5 Years of FOS, ed. A. Mehta, M. Beck, and G. Sunder-Plassmann. Oxford: Oxford PharmaGenesis.Google Scholar
- Thomas, G. 2014, February 7. Oakland Pediatrician Opens Her Home To Patients. NBC Bay Area.Google Scholar
- Topol, E. 2015. The Patient Will See You Now: The Future of Medicine Is in Your Hands, 1st ed. Basic Books, New York.Google Scholar
- Volokh, E. 2007. Medical Self-Defense, Prohibited Experimental Therapies, and Payment for Organs. Harvard Law Review 20: 1813–1846.Google Scholar